Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Anne Marit de Groot"'
Autor:
Lisa H. Tostanoski, Abishek Chandrashekar, Shivani Patel, Jingyou Yu, Catherine Jacob-Dolan, Aiquan Chang, Olivia C. Powers, Daniel Sellers, Sarah Gardner, Julia Barrett, Owen Sanborn, Kathryn E. Stephenson, Jessica L. Ansel, Kate Jaegle, Michael S. Seaman, Maciel Porto, Megan Lok, Brittany Spence, Kathleen Cayer, Danielle Nase, Shaikim Holman, Heath Bradette, Swagata Kar, Hanne Andersen, Mark G. Lewis, Freek Cox, Jeroen T. B. M. Tolboom, Anne Marit de Groot, Dirk Heerwegh, Mathieu Le Gars, Jerald Sadoff, Frank Wegmann, Roland C. Zahn, Hanneke Schuitemaker, Dan H. Barouch
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-6 (2022)
NPJ Vaccines
NPJ Vaccines
SARS-CoV-2 Spike-specific binding and neutralizing antibodies, elicited either by natural infection or vaccination, have emerged as potential correlates of protection. An important question, however, is whether vaccine-elicited antibodies in humans p
Autor:
Jerald Sadoff, Mathieu Le Gars, Boerries Brandenburg, Vicky Cárdenas, Georgi Shukarev, Nathalie Vaissiere, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Mandy Jongeneelen, Krisztian Kaszas, Jeroen Tolboom, Gert Scheper, Jenny Hendriks, Javier Ruiz-Guiñazú, Frank Struyf, Johan Van Hoof, Macaya Douoguih, Hanneke Schuitemaker
Publikováno v:
Vaccine. 40(32)
Ad26.COV2.S is a well-tolerated and effective vaccine against COVID-19. We evaluated durability of anti-SARS-CoV-2 antibodies elicited by single-dose Ad26.COV2.S and the impact of boosting.In randomized, double-blind, placebo-controlled, phase 1/2a a
Autor:
Mathieu Le Gars, Jerald Sadoff, Mandy Jongeneelen, Dirk Heerwegh, Georgi Shukarev, Carla Truyers, Anne Marit de Groot, Gert Scheper, Jenny Hendriks, Boerries Brandenburg, Frank Struyf, Johan Van Hoof, Macaya Douoguih, Hanneke Schuitemaker
Publikováno v:
Open Forum Infectious Diseases
Background In a Phase 3 trial, the Janssen COVID-19 vaccine, Ad26.COV2.S, showed robust efficacy against severe–critical COVID-19 in countries where different SARS-CoV-2 variants were circulating. We evaluated Ad26.COV2.S-elicited antibody neutrali